BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 21763969)

  • 1. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
    McDermott DF; George DJ
    Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Rini BI
    Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
    Schmidinger M; Bellmunt J
    Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
    Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
    Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
    Powles T
    Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.